Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in active ulcerative colitis (China phase 3)
CTR20132140Phase 3Completed
- Sponsor
- Janssen Biotech
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in autoimmune colitis, sponsored by Janssen Biotech. Started Apr 2015; status: completed.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20132140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132140.